[SCHEDULE 13G] Vera Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Kynam Capital Management, LP, Kynam Capital Management GP, LLC and individual Yue Tang report shared beneficial ownership of 3,426,887 shares of Vera Therapeutics Class A common stock, representing 5.37% of the class. The filing shows no sole voting or dispositive power; instead the reporting persons disclose shared voting and shared dispositive power over the full block of shares.

The signatories certify the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing identifies the reporting persons and their citizenships but does not name any group members or subsidiaries as acquiring parties.

Positive

• Transparent disclosure of a >5% stake: 3,426,887 shares representing 5.37% of Class A common stock
• Certification that the shares are held in the ordinary course of business and not to change or influence control

Negative

• None.

Insights

Securities Analyst

TL;DR: Kynam discloses a meaningful >5% stake (3.43M shares, 5.37%) held with shared voting/dispositive power.

The Schedule 13G shows Kynam entities and Yue Tang collectively hold 3,426,887 shares (5.37%) of Vera Therapeutics Class A stock, with shared voting and dispositive power and no sole control. The filing includes a certification that holdings are in the ordinary course and not intended to change control, consistent with a passive investor disclosure rather than an activist posture. For investors, this is a material ownership disclosure but contains no indications of an intent to influence corporate governance.

Corporate Governance Expert

TL;DR: Ownership disclosed is material for reporting but the filing expressly denies intent to influence control.

From a governance perspective, the report identifies shared voting/dispositive authority over a 5.37% position and explicitly states the securities are held in the ordinary course of business and not to effect control changes. Item responses show no group affiliation or subsidiary acquisition reported. The disclosure increases transparency about significant holders but does not, on its face, signal an active governance campaign.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Vera Therapeutics, Inc.

(Name of Issuer)

Class A common stock, $0.001 par value per share

(Title of Class of Securities)

92337R101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 92337R101

1

Names of Reporting Persons

Kynam Capital Management, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,426,887.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,426,887.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,426,887.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.37 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 92337R101

1

Names of Reporting Persons

Kynam Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,426,887.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,426,887.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,426,887.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.37 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 92337R101

1

Names of Reporting Persons

Yue Tang

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,426,887.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,426,887.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,426,887.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.37 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Vera Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 2000 Sierra Point Parkways, Suite 1200, Brisbane, CALIFORNIA 94005
Item 2.
(a)	Name of person filing: Kynam Capital Management, LP Kynam Capital Management GP, LLC Yue Tang
(b)	Address or principal business office or, if none, residence: 221 ELM ROAD PRINCETON, New Jersey 08540
(c)	Citizenship: Kynam Capital Management, LP - DELAWARE Kynam Capital Management GP, LLC - DELAWARE Yue Tang - UNITED STATES
(d)	Title of class of securities: Class A common stock, $0.001 par value per share
(e)	CUSIP No.: 92337R101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,426,887
(b)	Percent of class: 5.37 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Kynam Capital Management, LP - 0 Kynam Capital Management GP, LLC - 0 Yue Tang - 0
	(ii) Shared power to vote or to direct the vote: Kynam Capital Management, LP - 3,426,887 Kynam Capital Management GP, LLC - 3,426,887 Yue Tang - 3,426,887
	(iii) Sole power to dispose or to direct the disposition of: Kynam Capital Management, LP - 0 Kynam Capital Management GP, LLC - 0 Yue Tang - 0
	(iv) Shared power to dispose or to direct the disposition of: Kynam Capital Management, LP - 3,426,887 Kynam Capital Management GP, LLC - 3,426,887 Yue Tang - 3,426,887
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kynam Capital Management, LP

Signature:	Yue Tang
Name/Title:	Managing Member
Date:	08/14/2025

Kynam Capital Management GP, LLC

Signature:	Yue Tang
Name/Title:	Managing Member
Date:	08/14/2025

Yue Tang

Signature:	Yue Tang
Name/Title:	Self
Date:	08/14/2025

FAQ

How many Vera Therapeutics (VERA) shares does Kynam report owning?

The filing reports 3,426,887 shares, representing 5.37% of Vera Therapeutics Class A common stock.

Which entities and individuals filed the Schedule 13G for VERA?

The filing lists Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang as the reporting persons.

What voting and dispositive power is reported by the filers for VERA?

The filers report 0 shares with sole voting or dispositive power and 3,426,887 shares with shared voting and shared dispositive power.

Does the Schedule 13G indicate the position was acquired to influence control of Vera Therapeutics (VERA)?

No. The certification states the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Does the filing identify any group members or subsidiaries as acquiring the securities?

Item responses show 'Not Applicable' for group and subsidiary identifications, and no group affiliation is indicated.

When were the signatures provided on this Schedule 13G?

The signature blocks show the filing was signed by the reporting persons on 08/14/2025.